Cell death induced by N-(4-hydroxyphenyl)retinamide in human epidermal keratinocytes is modulated by TGF-β and diminishes during the progression of squamous cell carcinoma

International Journal of Cancer

Volumn 119, Issue 12, 2006, Pages 2803-2811

  Davies, Maria ^a   Paterson, Ian C ^a   Ganapathy, Anu ^a   Prime, Stephen S ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

4 HPR; Apoptosis; Carcinogenesis; Keratinocyte; TGF

Indexed keywords

FENRETINIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL LINE; CELL LINE HACAT; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; EPIDERMIS CELL; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; KERATINOCYTE; METASTASIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE; CELL PROLIFERATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FENRETINIDE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; KERATINOCYTES; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 33751583642     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22263     Document Type: Article

References (65)

1. Karagas MR, Stukel TA, Greenberg ER, Baron JA, Mott LA, Stem RS. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992;267:3305-10.
2. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992;327:1649-62.
3. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 1997;53:358-88.
4. Zakrzewska JM, Chan ES, Thornhill MH. A systematic review of placebo-controlled randomized clinical trials of treatments used in oral lichen planus. Br J Dermatol 2005;153:336-41.
5. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2005;54:150-80.
6. De Palo G, Formelli F. Risks and benefits of retinoids in the chemoprevention of cancer. Drug Safety 1995;13:245-56.
7. Formelli F, Barua AB, Olson JA. Bioactivities of N-(4-hydroxylphenyl) retinamide and retinoyl β-glucuonide. FASEB J 1996;10:1014-24.
8. Moon RC, Pritchard JF, Mehta RG, Nomides CT, Thomas CF, Dinger NM. Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide following surgical removal of first palpable tumor. Carcinogenesis 1989;10:1645-9.
9. Formelli F, Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 1993;51:5374-6.
10. Pienta KJ, Nguyen NM, Lehr JE. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 1993;53:224-6.
11. De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B, Descensi A, Veronesi U. Effect of fenretinide on ovarian cancer occurrence. Gynecol Oncol 2002;86:24-7.
12. Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, Crose N, Cavadini E, Formelli F, Costa L, Giardini R, Zurrida S, Costa A, et al. Randomised trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 2005;115:625-9.
13. Sun S-Y, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002;41:41-55.
14. Follen M, Atkinson EN, Schottenfeld D, Malpica A, West L, Lippman S, Zou C, Hittelman WN, Lotan R, Hong WK. A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intra-epithelial lesions of the cervix. Clin Cancer Res 2001;7:3356-65.
15. Descensi A, Serrano D, Bonanni B, Cazzaniga M, Guerrieri-Gonzaga A. Breast cancer prevention trials using retinoids. J Mammary Gland Biol Neoplasia 2003;8:19-30.
16. Puduvalli VK, Yung WK, Hess KR, Kuhn KR, Groves MD, Levin VA, Zweibel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, et al. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: a North American brain consortium study. J Clin Oncol 2004;22:4282-9.
17. Wu JM, DiPietrantonio AM, Hsieh TC, Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 2001;6:377-88.
18. Fanjul AN, Delia D, Pierotti MA, Rideout D, Qiu J, Pfahl M. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996;271:22441-6.
19. Sun S-Y, Li W, Yue P, Lippman SM, Hong WK, Lotan R. Mediation of N-(4-hydroxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 1999;59:2493-8.
20. Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM, Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenly)retinamide in F9 embryonal carcinoma cells. Cancer Res 1999;59:14-18.
21. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997;89:1191-8.
22. Delia D, Aiello A, Meroni L, Nocolini M, Reed JC, Pierotti MA. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 1997;18:943-8.
23. Hail N, Lotan R. Mitochondrial permeability transition is a central coordinating event in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Cancer Epidemiol Biomarkers Prev 2000;9:1293-1301.
24. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91:1138-46.
25. Corazzari M, Lovat PE, Oliverio S, Di Sano F, Donnorso RP, Redfern CPF, Piacentini M. Fenretinide: a p53-independent way to kill cancer cells. Biochem Biophys Res Commun 2005;331:810-15.
26. Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal 1999;11:1-14.
27. Roberson KM, Penland SN, Padilla GM, Selvan RS, Kim CS, Fine RL, Robertson CN. Fenretinide: induction of apoptosis and endogenous transforming growth factor β in PC-3 prostate cancer cells. Cell Growth Differ 1997;8:101-11.
28. Herbert BS, Sanders BG, Kline K. N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-β and induction of apoptosis in human breast cancer cells. Nutr Cancer 1999;34:121-32.
29. De Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-β signalling in cancer. J Natl Cancer Inst 2000;92:1388-1402.
30. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003;3:807-19.
31. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor β signaling impairs neu-induced mammary tumorigenesis while promoting pulmonary metastases. Proc Natl Acad Sci USA 2003;100:8430-5.
32. Tang B, Vu M, Booker T, Santner S, Miller FR, Anver MR, Wakefield LM. TGF-β switches from tumour suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003;112:1116-24.
33. Fusenig NE, Boukamp P. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumour progression of human skin keratinocytes. Mol Carcinog 1998;23:144-58.
34. Boukamp P, Stanbridge EJ, Foo DY, Cerutti PA, Fusenig NE. c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res 1990;50:2840-7.
35. Davies M, Robinson M, Smith E, Huntley S, Prime S, Paterson I. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinoctyes by TGF-β1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem 2005;95:918-31.
36. Huntley SP, Davies M, Matthews JB, Thomas G, Marshall J, Robinson CM, Eveson JW, Paterson IC, Prime SS. Attenuated type II TGF-β receptor signalling in human malignant oral keratinocyte cell lines induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination. Int J Cancer 2004;110:170-6.
37. Prime SS, Matthews JB, Patel V, Game SM, Donnelly M, Stone A, Paterson IC, Sandy JR, Yeudall WA. TGF-β receptor regulation mediates the response to exogenous ligand but is independent of the degree of cellular differentiation in human oral keratinocytes. Int J Cancer 1994;56:406-12.
38. Griffiths MR, Black EJ, Culbert AA, Dickens M, Shaw PE, Gillespie DA, Tavare JM. Insulin-stimulated expression of c-fos, fral and c-jun accompanies the activation of the activator protein-1 (AP-1) transcription complex. Biochem J 1998;335:19-26.
39. Game SM, Huelson A, Patel V, Donnelly M, Yeudall WA, Stone A, Fusenig NE, Prime SS. Progressive abrogation of TGF-β1 and EGF growth control is associated with tumour progression in Ras-transfected human keratinocytes. Int J Cancer 1992;52:461-70.
40. Tian F, DaCosta Byfield S, Parks WT, Yoo S, Felici A, Tang B, Piek E, Wakefield LM, Roberts AB. Reduction in Smad2/3 signalling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 2003;63:8284-92.
41. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerin T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999;91:1847-56.
42. Kabbout M, Hatoum A, Abou-Lteif G, Chakroun I, Homaidan FR, Darwiche N. Stage specific effect of N-(4-hydroxyphenyl)retinamide on cell growth in squamous cell carcinogenesis. Mol Carcinog 2004;40:12-23.
43. Xu H, Cheepala S, McCauley E, Coombes K, Xiao L, Fischer SM, Clifford JL. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumour suppression. Clin Cancer Res 2006;12:969-79.
44. Hail N, Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl)retinamide. J Biol Chem 2001;276:45614-21.
45. Moglia D, Formelli F, Baliva G, Bono A, Accetturi M, Nava M, De Palo G. Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses. Cancer Lett 1996;110:87-91.
46. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pitoia V, Raffaghello L, Rozzo C, Montaldo PG. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 1995;55:853-61.
47. Springer LN, Stewart BW. N-(4-hydroxyphenyl)retinamide-induced death in human lymphoblastoid cells:50kb DNA breakage as a means of distinguishing apoptosis from necrosis. Cancer Lett 1998;128:189-96.
48. Igawa M, Tanabe T, Chodak GW, Rukstalis DB. N-(4-hydroxyphenyl)retinamide induces cell cycle specific growth inhibition in PC3 cells. Prostate 1994;24:299-305.
49. Hsieh TC, Wu JM. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression. Prostate 1997;33:97-104.
50. Jinno H, Steiner MG, Mehta RG, Osborne MP, Telang NT. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide. Carcinogenesis 1999;20:229-36.
51. Lovat PE, Ranalli M, Annichiarrico-Petruzzelli M, Bernassola F, Piacentini M, Malcolm AJ, Pearson ADJ, Melino G, Redfern CPF. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. Exp Cell Res 2000;260:50-60.
52. Bruno S, Tenca C, Saverino D, Ciccone E, Grossi CE. Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment. Carcinogenesis 2002;23:447-56.
53. Creek KE, Geslani G, Batova A, Pirisi L. Progressive loss of sensitivity to growth control by retinoic acid and transforming growth factor-β at late stages of human papillomavirus type 16-initiated transformation of human keratinocytes. Adv Exp Med Biol 1995;375:117-35.
54. Borger DR, Mi Y-d, Geslani G, Zyzak LL, Batova A, Engin TSW, Pirisi L, Creek KE. Retinoic acid resistance at late stages of human papillomavirus type 16-mediated transformation of human keratinocytes arises despite intact retinoid signalling and is due to a loss of sensitivity to transforming growth factor-β. Virology 2000;270:397-407.
55. Mi Y, Borger DR, Fernandes PR, Pirisi L, Creek KE. Loss of transforming growth factor-β (TGF-β) receptor type I mediates TGF-β resistance in human papillomavirus type 16-transformed human keratinocytes at late stages of in vitro progression. Virology 2000;270:408-16.
56. Glick AB, Flanders KC, Danielpour D, Yuspa SH, Sporn MB. Retinoic acid induces transforming growth factor-β2 in cultured keratinocytes and mouse epidermis. Cell Regul 1989;1:87-97.
57. Fischer U, Janicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003;10:76-100.
58. Schulz A, Bauer G. Synergistic action between tumour necrosis factor-α and transforming growth factor type-β: consequences for natural antitumour mechanisms. Anticancer Res 2000;20:3443-8.
59. Ahmed MM, Alcock RA, Chendil D, Dey S, Das A, Venkatasubbarao K, Mohiuddin M, Sun L, Strodel WE, Freeman JW. Restoration of transforming growth factor-β signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2. J Biol Chem 2002;277:2234-46.
60. Wahl SM, Orenstein JM, Chen W. TGF-β influences the life and death decisions of T lymphocytes. Cytokine Growth Factor Rev 2003;14:85-9.
61. Thavaraj S, Paterson IC, Hague A, Prime SS. Over-expression of TGF-β1 in Smad-4 deficient human oral carcinoma cells causes tumour regression in vivo by mechanisms that sensitize cells to apoptosis. J Pathol 2005;205:14-20.
62. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anti-cancer drugs. Nat Rev Cancer5: 2005;297-309.
63. Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB. N-(4-hydroxyphenyl) retinamide inhibits invasion, suppresses osteoclastogenesis and potentiates apoptosis through down-regulation of IκBα kinase and nuclear factor-κB-regulated gene products. Cancer Res 2005;65:9555-65.
64. Park J-H, Liu L, Kim I-H, Kim J-H, You K-R, Kim D-G. Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells. Cancer Res 2005;65:2804-14.
65. Sanchez-Capelo A. Dual role for TGF-β1 in apoptosis. Cytokine Growth Factor Rev 2005;16:15-34.